Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intensified CHOP plus G-CSF versus standard CHOP in intermediate-prognosis non-Hodgkin lymphoma
ISRCTN11397785Phase 3Completed
- Sponsor
- Erasmus MC
- Start
- Nov 1994
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of cyclophosphamide, doxorubicin, vincristine, prednisone and filgrastim in non-Hodgkin lymphoma (NHL) (2 arms), sponsored by Erasmus MC. Primary endpoints: Complete response rate and Overall survival. Started Nov 1994; status: completed.
02
Drugs
cyclophosphamidedoxorubicinvincristineprednisonefilgrastim
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on ISRCTN11397785.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN11397785.